Traduzione in corso

Early Clinical Development of ARQ 197, a Selective, Non–ATPCompetitive

Inhibitor Targeting MET Tyrosine Kinase for the

Treatment of Advanced Cancers

ALEX A. ADJEI, BRIAN SCHWARTZ, EDWARD GARMEY

doi: 10.1634/theoncologist.2010-0380

 

Parole chiave: c-MET • EGFR • Epithelial growth factor inhibitor • Kinase receptor inhibitor • Hepatocyte growth factor

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s